A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung Eun | - |
dc.contributor.author | Jung, Hye-Kyung | - |
dc.contributor.author | Kang, Seung Joo | - |
dc.contributor.author | Lee, Yong Chan | - |
dc.contributor.author | Yang, Hyo-Joon | - |
dc.contributor.author | Park, Seon-Young | - |
dc.contributor.author | Shin, Cheol Min | - |
dc.contributor.author | Lim, Hyun Chul | - |
dc.contributor.author | Kim, Jie-Hyun | - |
dc.contributor.author | Nam, Su Youn | - |
dc.contributor.author | Shin, Woon Geon | - |
dc.contributor.author | Park, Jae Myung | - |
dc.contributor.author | Choi, Il Ju | - |
dc.contributor.author | Kim, Jae Gyu | - |
dc.contributor.author | Choi, Miyoung | - |
dc.date.accessioned | 2021-08-19T05:40:19Z | - |
dc.date.available | 2021-08-19T05:40:19Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1738-3331 | - |
dc.identifier.issn | 2671-826X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/48725 | - |
dc.description.abstract | Background/Aims: The eradication rate of the first-line standard triple therapy (STT) for Helicobacter pylori (H. pylori) infection has decreased since 2000; therefore, other first-line therapies are required. This study was aimed at investigating the efficacy of bismuth- containing quadruple therapy (PBMT) for first-line H. pylori eradication compared to STT, sequential therapy (SQT), and concomitant therapy (CT). Materials and Methods: The Ovid-MEDLINE, Koreamed, EMBASE, KMBASE, and Cochrane Library databases were searched from January 2008 to July 2018. All identified randomized controlled trials (RCTs) comparing PBMT and non-PBMT for first-line H. pylori eradication therapy were included in the final analysis. Results: A total of 3,653 patients from seven RCTs were enrolled. The pooled eradication rates of PBMT by intention-to-treat (ITT) and per-protocol (PP) analyses were 82.1% (95% CI, 68.2~90.8%) and 88.8% (95% CI, 77.1~94.9%), respectively. However, no statistically significant difference was observed in eradication rates of the 10- or 14-day PBMT as compared to 14-day STT, 10-day SQT, and 10-day CT in ITT and PP analyses. PBMT was significantly higher in adverse events than in the other eradication regimens (RR, 1.64; 95% CI, 1.11~2.44). Considerable heterogeneity in adverse events was observed among studies (χ2=88.7; P<0.001, I2=93%). Conclusions: PBMT can be the first-line treatment for H. pylori eradication in Korea when other first-line options, including STT, SQT, or CT, are unavailable due to their high adverse event rates. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한상부위장관ㆍ헬리코박터학회 | - |
dc.title | A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.7704/kjhugr.2020.0052 | - |
dc.identifier.bibliographicCitation | Korean Journal of Helicobacter Upper Gastrointestinal Research, v.21, no.1, pp 48 - 58 | - |
dc.identifier.kciid | ART002693261 | - |
dc.description.isOpenAccess | Y | - |
dc.citation.endPage | 58 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 48 | - |
dc.citation.title | Korean Journal of Helicobacter Upper Gastrointestinal Research | - |
dc.citation.volume | 21 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Adverse effects | - |
dc.subject.keywordAuthor | Bismuth tripotassium dicitrate | - |
dc.subject.keywordAuthor | Disease eradication | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.